Search PubMed⌕ Search

Biomedical subjects

W Cendrowski

Publications and source records attributed to W Cendrowski.

At least 37 records · Page 2Linked to original sources
PubMed1982

Sensitization of cerebrospinal fluid and peripheral blood lymphocytes to myelin basic protein in multiple sclerosis.

Cerebrospinal fluid (CSF) and peripheral blood (PB) lymphocyte sensitization to rabbit myelin basic protein (MBP) in 44 multiple sclerosis (MS) patients, 21 patients with other neurological diseases (OND) and 14 persons with neurosis was studied with the antigen-active rosette forming cells (Ag-ARFC) assay. The frequency of sensitization of CSF lymphocytes to MBP in groups of MS patients in the relapse stage and the chronic progressive stage was higher than in the group of MS patients in the stable stage and the OND patients. None of the healthy subjects showed a positive reaction with MBP. In BP there were no differences in the incidence of sensitization to MBP between patients in various stages of the disease, but it was higher than in the group of patients with OND and neuroses. In the patients who had suffered from MS for less than 4 years, sensitization to MBP was more common in CSF lymphocytes than in BP lymphocytes. The results suggest that primary sensitization to MBP occurs in CSF, and is probably secondary to myelin damage. However at present it is difficult to determine the extent to which sensitization of CSF and PB lymphocytes to MBP play a role in further demyelination processes.

Adolescent↗
PubMed1980

Lymphocyte subpopulations in the cerebrospinal fluid and peripheral blood in multiple sclerosis.

Subpopulations of lymphocytes in the CSF and peripheral blood were studied in 30 patients with MS, 16 with other neurological diseases (OND) and 15 control subjects without any neurological abnormalities. In patients with relapse of MS, the absolute numbers of total lymphocytes, alpha-naphthyl acid esterase (ANAE) positive, E-rosette forming and bearing the "avid" FcIgG receptor lymphocytes were significantly increased in the CSF as compared with stable or slowly progressive MS patients, patients with other OND and control subjects. The relative number of ANAE-positive cells was higher, and "avid"FcIgG receptor bearing cells lower in the CSF of all patients with MS than in the two other groups. The significance of the finding is unclear. The imbalance between lymphocyte subpopulations may reflect a primary defect in MS, or may be secondary, due to the presence of circulating immune complexes. In peripheral blood no substantial differences in lymphocyte behavior were observed between MS patients and other groups.

Adolescent↗
PubMed1980

Clinical impressions on the treatment of multiple sclerosis with thymus factor.

Nonspecific stimulation either with unfractionated thymus factor (TF) or fractions IV and VIII of TF was carried out in 13 patients with clinically definite multiple sclerosis (MS). Thymus hormones were given in a daily dose of 10 mg from 1 to 14 months. Three patients became non-tolerant to TF and were undergoing the treatment with TF IV or TF VIII. After immunostimulation 8 remained unchanged, 2 slowly improved (by one degree in Kurtzke's scale), 2 markedly worsened and 1 died. Five patients suffered 8 relapses, 3 showed slow progression and 2 developed either acute nephropyelitis or periodontitis. During this brief therapy, no convincing conclusion may be drawn regarding the effect upon the clinical course, although there is suggestion that thymus factor does not abolish the relapses in multiple sclerosis.

Adult↗
PubMed1979

Antilymphocyte globulin and adrenal steroids in the treatment of multiple sclerosis: short report based on seven cases.

A therapeutic trial of antilymphocyte globulin (ALG) combined with dexamethasone was carried out in 7 patients with chronic, relapsing multiple sclerosis. ALG was given intravenously in daily doses of 0.25-0.5 g on the weekdays over 1 to 2 months. Total doses of ALG ranged from 12.5 to 17.7 g. Follow-up made after 1 year showed that 2 had no deterioration and 2 became worse in "tolerant" group, and 2 showed no deterioration and 1 revealed fatal progression in "non-tolerant" group. The treatment proved to be toxic in 3 patients. This pilot study suggests that ALG enhances anti-inflammatory activity of adrenal steroids in some patients, but does not seem to change natural course of the disease.

Adult↗
PubMed1978

Levamisole in multiple sclerosis; with special reference to immunological parameters. A pilot study.

Nineteen patients with multiple sclerosis (MS) have been given one course of levamisole therapy, and 16 patients two courses of levamisole treatment in daily dosages of 100--150 mg over two periods lasting from 1 month to 22 weeks each. Clinical effect was evaluated using Kurtzke's disability status scale. Immediate clinical evaluation showed that 15 patints remained unchanged, two improved and two became worse. Follow-up revealed after 4--14 months that another four patients deteriorated and none improved. Altogether 10 patients developed 13 relapses. During this brief therapy, no convincing conclusions may be drawn regarding an influence upon the course of the disease, although there is the suggestion that levamisole was not beneficial in MS patients. There was no statistically significant effect of levamisole on peripheral blood lymphocyte count, lymphocyte stimulation tests, leucocyte migration inhibition tests, short and long incubation E-rosette forming cells and serum IgA, IgG or IgM levels. A group of MS patients showed after 1 month of levamisole treatment either short-lasting restored or potentiated skin hypersensitivity to bacterial and fungal antigens (P less than 0.05).

Administration, Oral↗
PubMed1978

[Haptoglobin levels in the serum and the cerebrospinal fluid patients with multiple sclerosis].

In 47 patients with multiple sclerosis and 10 with other diseases of the nervous system determinations of haptoglobin were performed in the serum and cerebrospinal fluid by the method of Owen et al. The Hp level in the serum of multiple sclerosis patients was normal. Its level in the cerebrospinal fluid was higher in multiple sclerosis patients than in cases of other nervous system diseases (statistically significant difference, p less than 0.001). Raised value of the Hp/IgG index in the cerebrospinal fluid of multiple sclerosis patients points to increased permeability of the blood-brain barrier. The so called normal Hp/IgG index was found in multiple sclerosis patients with high Hp and IgG level. Low Hp/IgG index suggested the possibility of IgG synthesis in the brain of patients with this disease. The comparison of the protein level and protein indexes showed that raised IgG level in the cerebrospinal fluid was present in 80% of multiple sclerosis cases, raised Kabat index in 50%, and low Hp/IgG index in 48%.

Haptoglobins↗
PubMed1977

Serological studies on the etiological role of measles-like virus in subacute sclerosing panencephalitis.

Significantly higher CSF titers of hemagglutination (HI) measles virus antibody were found in 22 patients with subacute sclerosing panencephalitis (SSPE) and more elevated titers of measles virus neutralization (NV) antibody were encountered in 19 patients with SSPE than in 50 children and young adults with other neurological diseases. Similar differences occurred in the sera of patients and controls. The serum: CSF antibody ratio was examined in 15 SSPE cases. All but one patient showed reduced antibody ratio (less than 80) as compared with the normal index. In addition, serological studies in some SSPE patients showed the presence of CSF antimeasles fluorescent (FA) and mixed hemadsorption (HAd) antibodies as well as serum anti-ribonucleoprotein antibody (RNP), HAd and FA had titers from 1:16 to 1:32000. SSPE patients harbored serum antibodies against three components of the measles virus as measles patients did. Most of SSPE patients had increasing CSF and serum titers of measles-like virus antibodies over the course of the disease.

Adolescent↗
PubMed1977

Clonazepam, baclofen and placebo in the treatment of spasticity.

25 patients with multiple sclerosis (MS) and other spastic disorders, 33 MS patients and 10 control patients with MS were given clonazepam, baclofen or placebo over a period of 5 days to 20 weeks. Both clonazepam and baclofen were significantly more effective than placebo in the treatment of spasticity (p less than 0.005 or p less than 0.01). A clinical trial of clonazepam versus baclofen was carried out and this showed no significant difference between the two drugs. However, there was indication that clonazepam influenced with better improvement in patients with slight muscle hypertonia mainly of cerebral origin. Patients with more severe forms, mainly of spinal spasticity, benefited rather from baclofen treatment (Fisher's test, p = 0.003). There was suggestion that combination of the two drugs may be more effective in some patients than than clonazepam or baclofen alone.

Adolescent↗
PubMed1976

Measles virus infection and multiple sclerosis: serological studies.

In 159 patients out of 161 with multiple sclerosis (MS), a significant rise in the level of measles hemagglutination inhibition (HI) antibody was found in the serum and in 92 MS patients the occurrence of measles HI antibody in the CSF was significantly more frequent. MS patients showed CSF humoral response against measles virus by neutralizing test (NV) (76%) more often than by hemagglutination test (37%). CSF FA antibody was found in 60%. In the serum of MS patients the presence of NV, HAd, FA, and GP-RNP was observed. 87% of MS patients showed lowered serum: CSF NV or HI antibody ratios and 78% had a diminished FA antibody ratio. Longitudinal study of serum HI measles virus antibody showed no substantial changes over longer period of the disease. Higher CSF measles antibody titer was found in more disabled patients with a malignant course of the disease (P less than 0.001). It is concluded that either persistent infection with proviruses or nonspecific stimulation of certain clones in individuals with genetic susceptibility provides for an excessive synthesis of humoral viral antibodies in MS.

Adolescent↗